Antibiotic dose impact on resistance selection in the community: A mathematical model of β-lactams and streptococcus pneumoniae dynamics

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2330-2337

  Opatowski, Lulla ^a,b   Mandel, Jonas ^a   Varon, Emmanuelle ^c   Boëlle, Pierre Yves ^d,e,f   Temime, Laura ^g   Guillemot, Didier ^a,b,h,i  

^a INSTITUT PASTEUR   (France)

^b INSERM U657   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g Unité de Recherches Mesures Physiques Métrologie   (France)

^h LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁱ RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; DOSE RESPONSE; DRUG EXPOSURE; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 77952652276     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00331-09     Document Type: Article

References (48)

1. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9:461-465.
2. Austin, D. J., K. G. Kristinsson, and R. M. Anderson. 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl. Acad. Sci. U. S. A. 96:1152-1156.
3. Ball, P. 2007. Conclusions: the future of antimicrobial therapy-Augmentin and beyond. Int. J. Antimicrob. Agents 30(Suppl.):S139-S141.
4. Bronzwaer, S. L., O. Cars, U. Buchholz, S. Molstad, W. Goettsch, I. K. Veldhuijzen, J. L. Kool, M. J. Sprenger, and J. E. Degener. 2002. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis. 8:278-282.
5. Cars, O., S. Molstad, and A. Melander. 2001. Variation in antibiotic use in the European Union. Lancet 357:1851-1853. (Pubitemid 32539121)
6. Centers for Disease Control and Prevention. 2004. Updated recommendations for use of pneumococcal conjugate vaccine. MMWR Morb. Mortal. Wkly. Rep. 53:177-178.
7. Cui, J., Y. Liu, R. Wang, W. Tong, K. Drlica, and X. Zhao. 2006. The mutant selection window in rabbits infected with Staphylococcus aureus. J. Infect. Dis. 194:1601-1608.
8. Drlica, K. 2003. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52:11-17.
9. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
10. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36(Suppl.):S42-S50.
11. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
12. Ekdahl, K., I. Ahlinder, H. B. Hansson, E. Melander, S. Molstad, M. Soderstrom, and K. Persson. 1997. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin. Infect. Dis. 25:1113-1117.
13. European Antimicrobial Resistance Surveillance System. October 2008, posting date. EARSS annual report 2007. http://www.rivm.nl/earss/result/ Monitoring-reports/.
14. Feikin, D. R., A. Schuchat, M. Kolczak, N. L. Barrett, L. H. Harrison, L. Lefkowitz, A. McGeer, M. M. Farley, D. J. Vugia, C. Lexau, K. R. Stefonek, J. E. Patterson, and J. H. Jorgensen. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90:223-229.
15. Fischbach, M. A., and C. T. Walsh. 2009. Antibiotics for emerging pathogens. Science 325:1089-1093.
16. Foster, K. R., and H. Grundmann. 2006. Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Med. 3:e29.
17. Geslin, P., A. Fremaux, G. Sissia, C. Spicq, and S. Aberrane posting date. Centre National de Référence des Pneumocoques, Rapport d'activité 1992-1997. http://www.invs.sante.fr/surveillance/cnr.
18. Goessens, W. H., J. W. Mouton, M. T. ten Kate, A. J. Bijl, A. Ott, and I. A. Bakker-Woudenberg. 2007. Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J. Antimicrob. Chemother. 59:507-516.
19. Goossens, H., M. Ferech, R. Vander Stichele, and M. Elseviers. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587. (Pubitemid 40247914)
20. Goossens, H., D. Guillemot, M. Ferech, B. Schlemmer, M. Costers, M. van Breda, L. J. Baker, O. Cars, and P. G. Davey. 2006. National campaigns to improve antibiotic use. Eur. J. Clin. Pharmacol. 62:373-379.
21. Guillemot, D., C. Carbon, B. Balkau, P. Geslin, H. Lecoeur, F. Vauzelle-Kervroedan, G. Bouvenot, and E. Eschwege. 1998. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279:365-370.
22. Guillemot, D., C. Carbon, F. Vauzelle-Kervroedan, B. Balkau, P. Maison, G. Bouvenot, and E. Eschwege. 1998. Inappropriateness and variability of antibiotic prescription among French office-based physicians. J. Clin. Epidemiol. 51:61-68.
23. Harbarth, S., W. Albrich, and C. Brun-Buisson. 2002. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg. Infect. Dis. 8:1460-1467.
24. Huchon, G. J., G. Gialdroni-Grassi, P. Leophonte, F. Manresa, T. Schaberg, and M. Woodhead. 1996. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur. Respir. J. 9:1590-1595.
25. Institut National de la Statistique et des Etudes Economiques. 2007, posting date. Indices et series statistiques. Démographie. http://www.indices.insee.fr/.
26. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
27. Levy, S. B., and B. Marshall. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10(Suppl.):S122-S129.
28. Lipsitch, M. 2001. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 32:1044-1054.
29. Mattoes, H. M., J. L. Kuti, G. L. Drusano, and D. P. Nicolau. 2004. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther. 26:1187-1198.
30. Melegaro, A., N. J. Gay, and G. F. Medley. 2004. Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol. Infect. 132: 433-441.
31. Mizrahi, A. N., and A. R. Mizrahi 2006, posting date. Taille poids surpoids obésité. French Institute for Research and information in health economics. http://argses.free.fr/textes/42-obesite-tpsof.pdf.
32. Mossong, J., N. Hens, M. Jit, P. Beutels, K. Auranen, R. Mikolajczyk, M. Massari, S. Salmaso, G. S. Tomba, J. Wallinga, J. Heijne, M. Sadkowska-Todys, M. Rosinska, and W. J. Edmunds. 2008. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5:e74.
33. Muller, A., S. Coenen, D. L. Monnet, and H. Goossens. 2007. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe, 1998-2005. Euro. Surveill. 12:E071011 1.
34. Negri, M. C., M. Lipsitch, J. Blazquez, B. R. Levin, and F. Baquero. 2000. Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob. Agents Chemother. 44:2485-2491.
35. Nicolau, D. P. 2008. Bugs versus drugs: what is the pharmacist's challenge? Am. J. Health Syst. Pharm. 65(Suppl.):S2-S3.
36. Odenholt, I., O. Cars, and E. Lowdin. 2004. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. J. Antimicrob. Chemother. 54:1062-1066.
37. Olofsson, S. K., and O. Cars. 2007. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin. Infect. Dis. 45(Suppl.):S129-S136.
38. Regev-Yochay, G., M. Raz, R. Dagan, N. Porat, B. Shainberg, E. Pinco, N. Keller, and E. Rubinstein. 2004. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin. Infect. Dis. 38:632-639.
39. Sabuncu, E., J. David, C. Bernede-Bauduin, S. Pepin, M. Leroy, P. Y. Boelle, L. Watier, and D. Guillemot. 2009. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med. 6:e1000084.
40. Schrag, S. J., C. Pena, J. Fernandez, J. Sanchez, V. Gomez, E. Perez, J. M. Feris, and R. E. Besser. 2001. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286:49-56.
41. Taubes, G. 2008. The bacteria fight back. Science 321:356-361.
42. Temime, L., P. Y. Boelle, P. Courvalin, and D. Guillemot. 2003. Bacterial resistance to penicillin G by decreased affinity of penicillin-binding proteins: a mathematical model. Emerg. Infect. Dis. 9:411-417.
43. Tomasz, A. 2000. Streptococcus pneumoniae: molecular biology & mechanisms of disease. Mary Ann Liebert, Inc., Larchmont, NY.
44. Trzcinski, K., C. M. Thompson, A. M. Gilbey, C. G. Dowson, and M. Lipsitch. 2006. Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J. Infect. Dis. 193:1296-1303.
45. Woodhead, M., G. Gialdroni Grassi, G. J. Huchon, P. Leophonte, F. Manresa, and T. Schaberg. 1996. Use of investigations in lower respiratory tract infection in the community: a European survey. Eur. Respir. J. 9:1596-1600.
46. World Health Organization Collaborating Center for Drug Statistics Methodology. August 2008, posting date. About the ATC/DDD system. World Health Organization, Oslo, Norway. http://www.whocc.no/atcddd.
47. Wutzke, S. E., M. A. Artist, L. A. Kehoe, M. Fletcher, J. M. Mackson, and L. M. Weekes. 2007. Evaluation of a national programme to reduce inappropriate use of antibiotics for upper respiratory tract infections: effects on consumer awareness, beliefs, attitudes and behaviour in Australia. Health Promot. Int. 22:53-64.
48. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl.):S147-S156.